Update on adverse drug events associated with parenteral iron. - Wikidata - awgldk - TriplyDB

Update on adverse drug events associated with parenteral iron.

Update on adverse drug events associated with parenteral iron.

http://www.wikidata.org/entity/Q46212164

about

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents Role of iron supplementation to erythropoiesis stimulating agents in the management of chemotherapy-induced anemia in cancer patients Safety of intravenous iron formulations: facts and folklore Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron Iron deficiency in gastrointestinal oncology The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guidel Anemia and iron deficiency in gastrointestinal and liver conditions Considerations and challenges in defining optimal iron utilization in hemodialysis Intravenous iron therapy: how far have we come?Safety of intravenous iron in hemodialysis patients.Ferumoxytol for the treatment of iron deficiency.Data mining of the public version of the FDA Adverse Event Reporting System Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms.Is low-molecular weight iron dextran really the most risky iron?--Unconvincing data from an unconvincing study.Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia Treatment of iron deficiency anemia associated with gastrointestinal tract diseases.A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.[Preoperative anemia in orthopedic surgery: clinical impact, diagnostics and treatment].The pharmacokinetics and pharmacodynamics of iron preparations.Alternative procedures for reducing allogeneic blood transfusion in elective orthopedic surgery.Diagnosis and management of iron deficiency anemia in patients with IBD.Indications and organisational methods for autologous blood transfusion procedures in Italy: results of a national survey Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management.Overview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia.Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the "Seville Document".Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases.Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients.Physical and chemical stability of iron sucrose in parenteral nutrition.Intravenous iron supplementation may be superior to observation in acute isovolemic anemia after gastrectomy for cancer Oh the irony: Iron as a cancer cause or cure?Anaphylaxis with elevated serum tryptase after administration of intravenous ferumoxytol.Management of Iron-Deficiency Anemia in Inflammatory Bowel Disease: A Systematic Review On the role of iron therapy for reducing allogeneic blood transfusion in orthopaedic surgery.Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations.Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model Is there any role of intravenous iron for the treatment of anemia in cancer?Relative Incidence of Acute Adverse Events with Ferumoxytol Compared to Other Intravenous Iron Compounds: A Matched Cohort Study.Efficacy and safety of intravenous iron sucrose in treating adults with iron deficiency anemia.The role of intravenous iron in the treatment of anemia in cancer patients

P2860

Q24186166-83B4B923-6ABE-4691-9CFE-5277D30263CE Q24203798-9BB3513F-7424-4AF3-9733-76B61821A09A Q26853397-52A0011B-A97E-47F1-9840-06BBE384FF09 Q27004170-8404137C-0A62-4AEC-99A1-B65D676B8B9E Q27023196-EF76EC32-D579-4231-980E-EE8838281B52 Q27024854-2476CE7F-FDC6-4265-9C1D-C55BA5C2B808 Q28069820-4D242F05-0ECE-411E-91DE-8A47F2D8977C Q28088564-B322E045-7F9C-417D-8860-0E58CD8AB388 Q28276678-2023B635-CCBF-48B4-A5F3-B206B3921982 Q30234981-A54CB067-7A0A-4841-B5D1-F4C32DFB641B Q30454001-19EC41B8-2742-48C0-93D6-FDE6BD0DF288 Q30651235-A6D8BD54-3385-49DA-9E58-ACB8719F3D1D Q30790443-94D08B47-A9B3-46A6-82F6-6A8BF7837EE9 Q31045009-D1B70921-F55C-4EC2-B3BE-900EB9A613C7 Q33607976-B9010AF3-18D6-458F-B9CD-AACD8970410A Q33903592-BE62D028-6881-4F10-920A-59EA2C4CD5D2 Q34010689-9BA27FE8-48EA-4201-BD54-F748D3F812FE Q34020541-A9F044AA-20C4-4459-B374-17A5C0730E8D Q34039226-C1DCF06D-6C6F-4E2D-90A8-687BDD274B48 Q34079843-32BFC593-8C77-44EB-8E98-65E9F3D49392 Q34141999-EF88CC9F-DFE1-4D66-9FD8-8CE91861DFC3 Q34416339-06D0EFA5-511E-49A4-BEA3-A20A10DDE366 Q34463623-5E97C217-5BC6-4041-A0AD-C78FD57143E4 Q34635638-F545D646-9766-4F80-A006-5594A3753312 Q34654443-3BA30E2A-ADD5-4FB9-A61A-2CCFA818EB4E Q34710712-B99E90A6-BCD4-482A-A365-3C73A019D7A1 Q34821739-0FA86742-55B4-4842-A769-9A5DF6D7D4AF Q34885195-8B8E1B86-57AF-450B-B229-99D97F28C4C2 Q35015688-7EF3FE1D-29C2-4753-8732-F8A5201EC9EE Q35109243-81189AEA-A1FD-4039-BFB6-E852DFE412A8 Q35343242-2D7A40AB-DD24-4F01-8A0E-67317DAEBF39 Q35574227-60A20C88-AF0C-4D46-ABF1-5C29D6BA50A0 Q35659768-298FE538-139E-48BA-9E79-231FE1028FCA Q35674624-17A3C2A7-108A-442E-A4A7-30521EAE9F02 Q35898038-871A72E3-7474-47BD-81D4-8E31EC3EF7B0 Q35931905-330A88E4-66B1-42C5-B7F1-A66087930623 Q36108113-75F9E983-FCB2-4CF7-A6DC-74DA319635D1 Q36263980-DB493696-268C-4C9F-A7CC-1DBF663B5057 Q36283062-E5038E6A-95FA-4293-9323-E27747578E5D Q36612686-57F6E0E2-E9A1-4B9C-A330-106C409B5728

P2860

Update on adverse drug events associated with parenteral iron.

http://www.wikidata.org/entity/Q46212164

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Update on adverse drug events associated with parenteral iron.

@en

Update on adverse drug events associated with parenteral iron.

@nl

type

label

Update on adverse drug events associated with parenteral iron.

@en

Update on adverse drug events associated with parenteral iron.

@nl

prefLabel

Update on adverse drug events associated with parenteral iron.

@en

Update on adverse drug events associated with parenteral iron.

@nl

P1433

Q46212164-51446E67-068F-41F5-9435-78F3C7E42961

P1476

Q46212164-462CDA68-D0D0-4B4D-8497-819A5BDE587B

P2093

Q46212164-110E2930-C4C5-4E7D-BEC9-371148C2D5CF

Q46212164-563AC4A3-CF6B-42E0-91B1-91EBB08B6864

Q46212164-822192FA-574E-44CF-900B-64441669BCA4

Q46212164-FE999B07-E185-4843-84C4-58C31C392F65

P2860

Q46212164-270D55FC-69B9-4E2E-8489-302BDA06E753

Q46212164-2A1BDD1F-90CD-40B5-AA15-4ECE7BE5CACD

Q46212164-311795B3-B198-48BC-8DB7-FEB091757085

Q46212164-4506836E-CC54-44E6-9F0B-6FB6FF9EC451

Q46212164-4506D5CC-57BD-4555-8D6A-477E7CF6B7EE

Q46212164-59264536-3F9B-4034-8643-19190369C685

Q46212164-7C2CE340-59CC-4E95-B663-327FF2B889C5

Q46212164-8CE9A534-8F93-46D5-AAC6-3F4B6C355B28

Q46212164-97E9F8F2-CCE2-4583-8986-C3820252595A

Q46212164-A5B74CDE-26EF-44FD-9322-90F4FEA995CF

P304

Q46212164-070B9282-398A-4D45-AF94-5A86C443DCED

P31

Q46212164-C35848DB-F156-4C3D-B98E-C0CB4F619C34

P356

Q46212164-60106CB4-8735-4A1A-A341-0B03A0C06665

P407

Q46212164-32FBD978-1401-4F68-A736-A1EF54CE1E28

P433

Q46212164-2B980C9C-3CC7-48EE-97F3-2FCF1B4B9AE1

P478

Q46212164-C801B0EF-E958-4429-9D76-2E429E69C8D9

P577

Q46212164-E94D9472-1AF2-43E6-8BA7-3DE7281EECD4

P5875

Q46212164-3E2158EF-20DF-4570-AA63-9E031A1C7218

P698

Q46212164-04B9B83F-2A88-4792-97C3-0821AF8606B1

P356

P1433

Nephrology Dialysis Transplantation

P1476

Update on adverse drug events associated with parenteral iron.

@en

P2093

Glenn M Chertow

http://www.w3.org/2001/XMLSchema#string

Jarl Ahlmén

http://www.w3.org/2001/XMLSchema#string

Odd Vaage-Nilsen

http://www.w3.org/2001/XMLSchema#string

Phillip D Mason

http://www.w3.org/2001/XMLSchema#string

P2860

On the relative safety of parenteral iron formulations

Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.

The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate.

Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.

Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity.

Parenteral iron nephrotoxicity: potential mechanisms and consequences.

Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.

Confidence intervals for the odds ratio in case-control studies: the state of the art.

Vector length as a proxy for the adequacy of ultrafiltration in hemodialysis.

Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease.

P304

378-382

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDT/GFI253

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2005-11-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7482862

http://www.w3.org/2001/XMLSchema#string

P698

16286429

http://www.w3.org/2001/XMLSchema#string